InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients

Stock Information for Quantum Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quantum Biopharma Ltd.

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC
Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
Quantum BioPharma Ltd. Provides Corporate Update
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.